ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login


 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
 News By Date

SuMoTuWeThFrSa
2627282930311
2345678
9101112131415
16171819202122
23242526272829
30123456

 Tuesday, June 18, 2013
 Top Breaking News
FDA Probes Deaths of Two Patients on Eli Lilly and Company (LLY) Schizophrenia Drug     More...
Amicus Therapeutics, Inc. (FOLD) Shelves New-Drug Filing for Fabry Disease Drug     More...
Roche (RHHBY)'s Avastin Approved in Japan for Treatment of Aggressive Brain Cancer     More...
 Featured Stories
Red-Meat Eaters Increase Risk of Diabetes With More Portions, JAMA Internal Medicine Reveals     More...
Paper Towels Better for Hand Hygiene Than Electric Dryers, Queensland University of Technology Study     More...
New Virus Isolated From Patients With Severe Brain Infections, Oxford University and University of Amsterdam Study     More...
Can an Artificial Sweetener Stop Parkinson's? Tel Aviv University Study     More...
Tough Guts of Female Mice Point to Colitis, Michigan State University Study     More...
Sibling Bullying Can Leave Lasting Scars, Pediatrics Reveals     More...
Testosterone Improves Verbal Learning and Memory in Postmenopausal Women, Monash University Study     More...
 More News
Santarus Inc. (SNTS) and Pharming Group (PHGUF.PK) Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application     More...
Immune Response BioPharma to Seek Approval of REMUNE With MCC of South Africa     More...
IntelGenx Corp. Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm™ Oral Film Product     More...
RedHill Biopharma Ltd. (RDHL) Announces FDA Acceptance for Review of RHB-103 NDA for Acute Migraine and PDUFA Goal Date of February 3, 2014     More...
Hyperion Therapeutics Announces RAVICTI and BUPHENYL Pharmacokinetic Analyses Reported in The Journal of Clinical Pharmacology     More...
Vanda Pharmaceuticals, Inc. (VNDA) Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm in Blind Patients With Non-24-Hour Disorder     More...
Ipsen (IPN.PA) Release: "PRIMARYS" Study Investigators Observed Clinically Relevant Results in an Investigational Phase III Study With Somatuline® Autogel® 120 mg in Patients With Acromegaly     More...
Adamas Pharmaceuticals Presents Positive Phase 2/3 Results for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson's Disease     More...
OncoSec Medical Inc. Announces Completion of Enrollment of Phase II Metastatic Melanoma Trial     More...
TWi Biotechnology Announces Completion of Patient Enrollment in Gout Flare Prophylaxis Phase II Trial for AC-201     More...
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Initiates Phase II Clinical Trial of Pracinostat and Vidaza® in Frontline Myelodysplastic Syndrome     More...
iCo Therapeutics Inc. Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema     More...
DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus     More...
PhaseBio Pharmaceuticals, Inc. Expands Clinical Development of Vasomera, an Investigational Treatment for Cardiopulmonary Diseases     More...
Vaxil Reports Promising Results From Its Follow-Up Clinical Trial of ImMucin in Multiple Myeloma a Patients     More...
Sanford-Burnham Medical Research Institute Researchers Develop Novel Drug That Reverses Loss of Brain Connections in Models of Alzheimer's     More...
Isotechnika Pharma Inc. (ISA.TO) Receives Additional Funding From the Government of Canada for the Preclinical Development of NICAM 440-02 as an Anti-Hepatitis C Agent     More...
ACADIA Pharmaceuticals, Inc. (ACAD) Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson’s Disease and Movement Disorders     More...